Kailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price reached a new 52-week low on Monday . The company traded as low as $16.37 and last traded at $16.56, with a volume of 39516 shares trading hands. The stock had previously closed at $17.17.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KLRA. Evercore initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating for the company. TD Cowen initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price for the company. Zacks Research raised Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Leerink Partners started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kailera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Down 2.3%

The company has a market capitalization of $2.17 billion and a PE ratio of -0.00. The company’s 50-day moving average price is $19.28.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, research analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KLRA. California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the second quarter valued at approximately $309,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the second quarter valued at $24,233,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new stake in Kailera Therapeutics in the 2nd quarter worth $113,923,000.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.